Folic Acid CAS NO.59-30-3

Folic acid Basic information
Description
Product Name:    Folic acid
Synonyms:    EZNA KIT FUNGAL DNA MINI;KIT BLOOD DNA EZNA 5 TESTS;PTEROYL-L-GLUTAMIC ACID;PTEROYLMONOGLUTAMIC ACID;PTEROYLGLUTAMIC ACID;PTEROYGLUTAMIC ACID;PTEGLU;PGA
CAS:    59-30-3
MF:    C19H19N7O6
MW:    441.4
EINECS:    200-419-0
Product Categories:    Inhibitors;Nutritional Supplements;Food and Feed Additive;Biochemistry;Vitamin Ingredients;food or feed additives;Vitamins;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;FOLICET;vitamin;raw material;Intermediates & Fine Chemicals;Pharmaceuticals;standardized herbal extract;59-30-3
Mol File:    59-30-3.mol
 

Folic acid Chemical Properties
Melting point     250 °C
alpha     20 º (c=1, 0.1N NaOH)
Boiling point     552.35°C (rough estimate)
density     1.4704 (rough estimate)
refractive index     1.6800 (estimate)
storage temp.     2-8°C
solubility     boiling water: soluble1%
form     Crystalline Powder
pka    pKa 2.5 (Uncertain)
color     Yellow to orange
Odor    Odorless
PH Range    4
Water Solubility     1.6 mg/L (25 ºC)
Merck     14,4221
BRN     100781
BCS Class    3
Stability:    Stable. Incompatible with heavy metal ions, strong oxidizing agents, strong reducing agents. Solutions may be light and heat sensitive.
InChIKey    OVBPIULPVIDEAO-LBPRGKRZSA-N
LogP    -0.990 (est)
CAS DataBase Reference    59-30-3(CAS DataBase Reference)
NIST Chemistry Reference    Folic acid(59-30-3)
EPA Substance Registry System    L-Glutamic acid, N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]- (59-30-3)
Safety Information
Risk Statements     33-62-68
Safety Statements     24/25
WGK Germany     1
RTECS     LP5425000
F     8
TSCA     Yes
HS Code     29362900
Hazardous Substances Data    59-30-3(Hazardous Substances Data)
Toxicity    A water soluble vitamin required in the diet of mammals. Sulfonamide drugs are selectively toxic to bacteria because they inhibit the incorporation of p-aminobenzoic acid into folic acid, a biosynthetic process in bacteria. Folic acid deficiency adversely affects prenatal development in humans. Dietary supplementation with folic acid dramatically reduces the incidence of neural tube defects in humans. Folic acid deficiency may also contribute to the causes of megaloblastic macrocytic anemia and a consequence of this is that this disease can be induced, as a side effect, when methotrexate, a folic acid antagonist, is used in cancer chemotherapy